Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H’24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the company has completed enrollment of the... Read More

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independent Data Safety Monitoring Board (DSMB) Planned for 1H’24 with Topline Results Expected 2H’24 Conference Call at 4:30 pm ET Today BOSTON, Feb. 28, 2024 (GLOBE... Read More

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, February 28, 2024, at 4:30 p.m. ET to report financial results for the fourth quarter and full year... Read More

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650 Patients in Monotherapy Arm; First Interim Analysis by the Independent Data Safety Monitoring Board (DSMB) Expected in March 2024 BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a... Read More

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 42 nd Annual J.P. Morgan Healthcare Conference on... Read More

First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study Plasma Pharmacokinetic (PK) Profiles of Bemnifosbuvir and Ruzasvir Were Not Affected by Food or Concomitant Dosing, Indicating Low Risk of Drug-Drug Interactions Bemnifosbuvir and Ruzasvir are Potent Direct Acting Antivirals In Vitro with Favorable Antiviral Profiles Against HCV NS5A and NS5B... Read More

Patient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24 Phase 2 bemnifosbuvir and ruzasvir combination trial for hepatitis C (HCV) advances, initial results from 60-patient lead-in cohort expected 1Q24 Conference call at 4:30 pm ET today BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or the... Read More

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in and present a business update at the following investor conferences in November. Jefferies London Healthcare... Read More

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced two upcoming poster presentations at The Liver Meeting 2023, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place from... Read More

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 8, 2023, at 4:30 p.m. ET to report financial results for the third quarter ended September... Read More

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc . (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat and present a business update at the Morgan Stanley 21 st Annual Global Healthcare Conference on... Read More

Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environment Enrollment continues in Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of hepatitis C (HCV) with initial results expected in 4Q23 Conference call at... Read More

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 8, 2023, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2023,... Read More

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the dosing of the first patient in the Phase 2 bemnifosbuvir and ruzasvir combination study for the treatment of Hepatitis C Virus (HCV) infection. “The initiation of this... Read More

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Thursday, June 8, 2023... Read More

BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that its Board of Directors unanimously rejected the unsolicited proposal from Tang Capital Partners, LP on behalf of Concentra Biosciences, LLC to acquire all outstanding... Read More

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of... Read More

Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV on track for first patient dosed 2Q23; initial results expected in 4Q23 Conference call at 4:30 pm ET today BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals,... Read More

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2023, and... Read More

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to bemnifosbuvir for the treatment of COVID-19. Bemnifosbuvir is an oral,... Read More

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of the full results from the MORNINGSKY Phase 3 trial evaluating bemnifosbuvir for the treatment of COVID-19. These results are being presented at the 33... Read More

Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as other human coronaviruses such as HCoV-229E, HCoV-OC43, and SARS-CoV-1 Favorable absorption, distribution, metabolism, and excretion profile demonstrated for bemnifosbuvir Synergistic antiviral effect observed... Read More

BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the 36 th International Conference on Antiviral Research (ICAR), which will take place March 13-17, 2023 in Lyon, France. Presentation... Read More

Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23 Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV to start enrollment in 2Q23; initial results expected by 4Q23 AT-752 dengue program results and update Conference call at 4:30 pm ET today BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Atea... Read More

Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that data from three Phase 1 studies suggest a favorable drug-drug interaction profile. No dosage adjustment is needed for CYP3A substrates or for drugs that are... Read More

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, February 28, 2023, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022, and to provide a business update. To access the live conference call,... Read More

BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22, 2023 in Seattle, Washington. Details for the poster presentations are as follows: Poster Number: 512 Title: No Dose Adjustments for... Read More

BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the SVB Securities Global Biopharma Conference on Tuesday, February... Read More

Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination Trial of Bemnifosbuvir and Ruzasvir in Patients Infected with Hepatitis C Virus (HCV) with Initial Results Anticipated 4Q23... Read More

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. PT in San Francisco, CA. A live webcast of the... Read More